Johnson & Johnson’s $7.5 Billion Registered Notes Offering
September 08, 2020
Cravath represented the underwriters, led by BofA Securities, J.P. Morgan Securities, Citigroup and Deutsche Bank Securities, in connection with the $7.5 billion registered notes offering of Johnson & Johnson, a company engaged in the research and development, manufacturing and sale of a broad range of products in the healthcare field. Proceeds of the offering will be used to finance the acquisition of Momenta Pharmaceuticals, Inc., by Johnson & Johnson and for general corporate purposes. The transaction closed on August 25, 2020.
The Cravath team included partner Craig F. Arcella and associate Saagar Kaul on capital markets matters, and associate Luis Calderon‑Gomez on tax matters. Bethany E. Clarke also worked on capital markets matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1998, Columbia Law SchoolHarlan Fiske Stone Scholar
-
B.A., 1995, Duke University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
November 17, 2025
Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.
On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
March 12, 2025
Johnson & Johnson’s $5 Billion Registered Notes Offering and Concurrent €4 Billion Notes Offering
Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.
